JPRN-UMIN000001437
Completed
Phase 2
Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer. - JACCRO CC-03
ConditionsColorectal cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Colorectal cancer
- Sponsor
- Japan Clinical Cancer Research Organization
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Contraindications of using CPT\-11, Bevacitumab, 5\-FU and Leucovorin (2\) Having double or more cancers within 5 yeras. (3\).Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant. (4\) Any subject judged by the investigator to be unfit for any reason to participate in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after progression on bevacizumab with oxaliplatine-based chemotherapy in patients with metastatic colorectal cancer whose KRAS status are investigated.Recurrent or metastatic colorectal cancerJPRN-UMIN000004219Hyogo Cancer Center, Dept. of Gastrointestinal and Hepatobiliary Oncology40
Completed
Phase 2
Phase II Study of FOLFIRI Plus Bevacizumab (AVASIRI) in Patients as Second Line Chemotherapy of Unresectable Colorectal CancerColorectal CancerJPRN-UMIN000001060ational Cancer Center Hospital, Gastrointestinal Oncology Division35
Completed
Phase 2
Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancerPatients with metastatic colorectal cancerJPRN-UMIN000017102Translational Research Informatics Center, Foundation for Biomedical Research and Innovation45
Active, not recruiting
Not Applicable
patients with colorectal carcinoma compared to patients with normal LDH serum levelspatients treated with first-line chemotherapy and bevacizumab will be prospectively stratified according to LDH serum levelsTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-005048-46-ITFondazione GISCAD
Recruiting
Phase 2
A phase II trial of FOLFOXIRI+Bevacizumab as preoperative chemotherapy for locally advanced lower rectal cancerower rectal cancerJPRN-UMIN000031028Kobe University Graduate School of Medicine40